REITs to Watch for Q2 Earnings on Jul 23: ADC, ACC and ELS
AbbVie Inc. ABBV announced new data from the phase II study on investigational JAK1 inhibitor, upadacitinib. The 52-week CELEST study evaluated upadacitinib in multiple dosing regimens through week 52 in adult patients with Crohn's disease and who were intolerant or had inadequate response to an immunomodulator or tumor necrosis factor alpha antagonist (TNF-a).
Patients who clinically responded to treatment in the 16-week induction phase maintained their response after the 36-week extension phaseof the study, which evaluated multiple dosing regimens of upadacitinib through week 52.
Please note that results from the 16-week induction phase from the CELEST study were previously announced in May last year.
The improvement seen in patients who were given higher doses (6 mg and 12 mg twice-daily) were numerically greater compared with 3 mg twice-daily at 52 weeks.
Results also showed that those patients who responded to upadacitinib induction treatment at week 16 achieved numerically higher rates of clinical remission and endoscopic response by patients receiving 12 mg dose in the extension phase compared with other other lower doses in 52 weeks.
The study showed that the overall safety profile of upadacitinib was consistent with that observed in other upadacitinib studies, with no new safety signals detected.
These data were presented at the 13th Congress of the European Crohn's and Colitis Organisation (ECCO) in Vienna, Austria.
AbbVie’s shares have rallied 92% over a year, outperforming the industry’s growth of 13%.
Separately at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego., the company presentedresults from a phase IIb study evaluating upadacitinib, in adult patients with moderate to severe atopic dermatitis.
Upadacitinib also is mainly being investigated in six phase III studies for rheumatoid arthritis. Other studies are also underway for the treatment of ulcerative colitis and psoriatic arthritis.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank & Other Stocks to Consider
AbbVie carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the health care space are Exelixis EXEL, XOMA Corp XOMA and Enanta Pharma ENTA. While Exelixis sports a Zacks Rank #1 (Strong Buy), XOMA and Enanta Pharma carry a Zacks Rank #2, each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exelixis’ earnings per share estimates have moved up from 73 cents to 77 cents for 2018 in the last 60 days. The company delivered positive earnings surprise in the last four quarters, with an average beat of 572.92%. Share price of the company moved up 26.2% over a year.
XOMA’s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 in the last 60 days. The company pulled off a positive earnings surprise in one of the last four quarters, with an average beat of 47.92%. Share price of the company skyrocketed 392.4% over a year.
Enanta Pharma delivered a positive earnings surprise in three of the last four quarters, with an average beat of 373.1%. Share price of the company surged 179.7% over a year.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
XOMA Corporation (XOMA) : Free Stock Analysis Report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
Enanta Pharmaceuticals, Inc. (ENTA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research